Adverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023 - Adverum Biotechnologies (NASDAQ:ADVM)

- Patients in OPTIC continue to experience long-term benefit from Ixo-vec through 3 years of follow-up, including maintenance of vision, durability of anatomical improvements and sustained reduction in anti-VEGF

Related Keywords

United Kingdom ,United States ,San Francisco ,California ,American ,Laurent Fischer ,Carld Regillo ,Carl Regillo ,Adverum Biotechnologies Inc ,European Medicines Agency ,Clinical Program Milestones ,Retina Service At Wills Eye Hospital ,Exchange Commission ,American Academy Of Ophthalmology ,Healthcare Products Regulatory Agency ,Drug Administration ,Retina Subspecialty Day ,American Academy ,Extension Data ,Gene Therapy ,Preliminary Data ,Year Results From ,Protein Data Highlights ,Baseline Characteristics ,Clinical Program ,Program Milestones ,Retina Service ,Wills Eye Hospital ,Fast Track ,Innovation Passport ,Private Securities Litigation Reform Act ,Quarterly Report ,